Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years and ≤75 years; 2. Histologically or cytologically confirmed SCLC; 3. No malignant pleural effusion or pericardial effusion; 4. No prior history of thoracic radiotherapy or thoracic surgery; 5. No prior systemic anti-tumor therapy; 6. ECOG performance status 0-2, with a life expectancy of ≥12 weeks; 7. At least one measurable lesion per RECIST 1.1 criteria; 8. No history of interstitial pneumonia; 9. No history of immune-related pneumonitis; 10. No history of autoimmune diseases; 11. No history of significant active pulmonary infection; 12. No use of corticosteroid therapy within 14 days prior to enrollment; 13. No Grade ≥3 hematologic toxicity or hepatic/renal impairment; 14. No brainstem metastases and no significant neurological symptoms; 15. For subjects with coexisting HBV/HCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy; 16. All subjects have provided written informed consent; Exclusion Criteria: 1. Presence of interstitial pneumonia or infectious fever prior to treatment; 2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment); 3. Prior history of thoracic radiotherapy or thoracic surgery; 4. Presence of Grade ≥3 hematologic toxicity or hepatic/renal impairment; 5. Hypersensitivity to adebrelimab; 6. Significant respiratory symptoms that preclude tolerance to radiotherapy; 7. Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above; 8. Presence of pleural effusion or pericardial effusion;